News
Serious Adverse Events Linked to Short-Term Corticosteroid Use
The data revealed the most common indications for short-term corticosteroid use to be upper respiratory tract infections, spinal conditions, and allergies.
Your search for oral corticosteroids returned 27 results
News
Fasenra Approved for Severe Eosinophilic Asthma
Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
News
Which Medications Are Prescribed Most Often for Atopic Dermatitis?
Male patients exhibited the highest rates of oral steroid prescriptions.
News
PANS/PANDAS Treatment Guidelines Released
"Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions," the authors write.
Drugs in the Pipeline
Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
News
Dupixent sBLA Gets Priority Review for Chronic Rhinosinusitis With Nasal Polyps Indication
Regeneron and Sanofi announced that the Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA included data from two phase 3 randomized, double-blind, placebo-controlled trials (SINUS-24…
News
FDA Approves Nucala for Severe Asthma
The FDA has approved Nucala (mepolizumab; GlaxoSmithKline) for injection as add-on maintenance treatment of patients with severe asthma aged ≥12 years.
Drugs in the Pipeline
Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis
Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
AAAAI 2017
Omalizumab Associated with Reduced Allergic Asthma Exacerbations, Hospitalizations
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
AAAAI 2017
Is IL-5 Inhibition Effective in NSAIDs-Exacerbated Respiratory Disease?
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
